Ideaya Biosciences, Inc. 8-K Filing
Ticker: IDYA · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Ideaya Biosciences, Inc. (ticker: IDYA) to the SEC on Dec 5, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq).
How long is this filing?
Ideaya Biosciences, Inc.'s 8-K filing is 2 pages with approximately 697 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 697 words · 3 min read · ~2 pages · Grade level 15.7 · Accepted 2025-12-05 16:19:17
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
Filing Documents
- d87387d8k.htm (8-K) — 24KB
- 0001193125-25-309716.txt ( ) — 135KB
- idya-20251204.xsd (EX-101.SCH) — 3KB
- idya-20251204_lab.xml (EX-101.LAB) — 18KB
- idya-20251204_pre.xml (EX-101.PRE) — 11KB
- d87387d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain statements contained herein are forward-looking statements, including, but not limited to, statements related to the transfer of IDE275 and IDE705 clinical programs from GSK to the Company and the cash runway guidance. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing or commercialization of drug products, the outcome of pricing, coverage and reimbursement negotiations with third-party payors for the Company's products, the Company's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed or furnished with the Securities and Exchange Commission.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: December 5, 2025 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer